Somewhat Positive Press Coverage Somewhat Unlikely to Impact SCYNEXIS (SCYX) Stock Price

Media coverage about SCYNEXIS (NASDAQ:SCYX) has trended somewhat positive recently, Accern Sentiment Analysis reports. The research group identifies positive and negative press coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. SCYNEXIS earned a daily sentiment score of 0.05 on Accern’s scale. Accern also assigned headlines about the company an impact score of 46.4602526974606 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

These are some of the news headlines that may have impacted Accern’s scoring:

Several analysts have recently commented on SCYX shares. ValuEngine cut shares of SCYNEXIS from a “sell” rating to a “strong sell” rating in a research note on Tuesday, August 22nd. Zacks Investment Research upgraded shares of SCYNEXIS from a “hold” rating to a “buy” rating and set a $2.00 target price for the company in a research note on Tuesday, August 29th. Aegis restated a “buy” rating on shares of SCYNEXIS in a research note on Tuesday, May 30th. Finally, Roth Capital set a $9.00 target price on shares of SCYNEXIS and gave the stock a “buy” rating in a research note on Monday, August 7th. One analyst has rated the stock with a sell rating, two have given a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. SCYNEXIS has a consensus rating of “Buy” and an average target price of $10.25.

Shares of SCYNEXIS (NASDAQ:SCYX) traded up 2.35% during trading on Tuesday, hitting $2.18. 243,841 shares of the stock were exchanged. The stock’s market cap is $58.25 million. SCYNEXIS has a 12-month low of $1.52 and a 12-month high of $5.51. The stock has a 50-day moving average of $1.83 and a 200 day moving average of $2.09.

In related news, Director David C. Hastings acquired 20,000 shares of SCYNEXIS stock in a transaction that occurred on Wednesday, June 21st. The stock was acquired at an average price of $1.75 per share, with a total value of $35,000.00. Following the completion of the acquisition, the director now directly owns 20,000 shares of the company’s stock, valued at approximately $35,000. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Insiders purchased 45,000 shares of company stock valued at $75,850 in the last ninety days. Corporate insiders own 3.91% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Somewhat Positive Press Coverage Somewhat Unlikely to Impact SCYNEXIS (SCYX) Stock Price” was reported by Chaffey Breeze and is the property of of Chaffey Breeze. If you are reading this report on another website, it was copied illegally and reposted in violation of US and international copyright legislation. The correct version of this report can be accessed at

SCYNEXIS Company Profile

SCYNEXIS, Inc is engaged in the discovery, development and commercialization of anti-infectives. The Company is developing its lead product candidate, SCY-078, as an oral and intravenous (IV) drug for the treatment of several fungal infections, including serious invasive fungal infections. SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo in animal studies against a range of Candida and Aspergillus species, including drug-resistant strains.

Insider Buying and Selling by Quarter for SCYNEXIS (NASDAQ:SCYX)

Receive News & Ratings for SCYNEXIS Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SCYNEXIS Inc. and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply